Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-09-29

FDA Approved: ADDYI — Supplemental Application (Sprout Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ADDYI (flibanserin) from Sprout Pharmaceuticals, resulting in an updated labeling for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ADDYI (flibanserin)

Snippet

SUPPL AP for ADDYI (FLIBANSERIN)